EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate

SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds. The full proceeds, when funded, are expected to fund the company through 2026 and topline Phase 2 results. The transaction is led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, and the JDRF T1D Fund. Al